Manufacturer with High Purity and Stable Quality
Supply Irinotecan and Related Intermediates:
Irinotecan Hydrochloride CAS: 100286-90-6
Irinotecan Free Base CAS: 97682-44-5
Irinotecan Hydrochloride Trihydrate CAS: 136572-09-3
7-Ethyl-10-Hydroxycamptothecin CAS: 86639-52-3
1-Chlorocarbonyl-4-Piperidinopiperidine Hydrochloride CAS: 143254-82-4
Chemical Name | Irinotecan Free Base |
CAS Number | 97682-44-5 |
CAT Number | RF-API51 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C33H38N4O6 |
Molecular Weight | 586.68 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Light Yellow Powder |
Identification HPLC | Retention time of sample corresponds to that of RS |
Loss on Drying | ≤5.0% |
Single Max. Impurity | ≤0.25% |
Total Impurities | ≤1.0% |
Assay | ≥99.0% (HPLC) |
Test Standard | Enterprise Standard |
Usage | API |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Irinotecan Free base is a camptothecin analog and topoisomerase I inhibitor. It may inhibit AChE. Irinotecan Free base is uesed to treat colon cancer, but it also moderates inhibition of dendritic cell differentiation and decreases the number of tumor vessels in glioma models. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].In Vivo:Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice.